| 3.65 -0.02 (-0.54%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.41  |
1-year : | 4.5 |
| Resists | First : | 3.77 |
Second : | 3.85 |
| Pivot price | 3.7 |
|||
| Supports | First : | 3.64 |
Second : | 3.02 |
| MAs | MA(5) : | 3.68 |
MA(20) : | 3.72 |
| MA(100) : | 3.82 |
MA(250) : | 7.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 15.9 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 15.73 | Low : | 2.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FULC ] has closed above bottom band by 12.4%. Bollinger Bands are 87.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 81 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.7 - 3.72 | 3.72 - 3.73 |
| Low: | 3.58 - 3.61 | 3.61 - 3.63 |
| Close: | 3.61 - 3.65 | 3.65 - 3.69 |
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Wed, 07 Oct 2026
Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of a Pending Securities Investigation - The National Law Review
Wed, 19 Aug 2026
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC - Business Wire
Mon, 17 Aug 2026
FULC: Merger forms a migraine-focused biotech with $245M financing and clinical milestones ahead - TradingView
Fri, 31 Jul 2026
Fulcrum Therapeutics: Buy It For The Strategic Reset (NASDAQ:FULC) - Seeking Alpha
Tue, 09 Jun 2026
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire
Fri, 05 Jun 2026
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 102.9 (%) |
| Shares Short | 7,110 (K) |
| Shares Short P.Month | 7,020 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -32.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.74 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -3.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|